2026-05-14 · 2026-05 / week-1

Redcentric Still Prices the Stub Too Cheap

Redcentric Still Prices the Stub Too Cheap

Summary: RCN last closed at 131.00p on May 13, 2026, the latest available close before the London market opened on May 14, 2026, while Redcentric is preparing a 160p equity tender after completing the sale of its data-centre business for estimated proceeds of GBP122.85 million and winning shareholder approval for the capital reduction needed to fund the return. At that quote, the market is not really arguing about a tender spread. It is pricing the surviving managed-services business at only about 115p per post-tender share, or roughly GBP118.7 million of residual equity value before any benefit from further retained sale proceeds. Redcentric sale completion RNS, May 1, 2026 Redcentric capital-reduction vote result, May 13, 2026 Redcentric H1 FY26 results presentation, December 10, 2025 Redcentric share-price page, latest close shown as 131.00p on May 13, 2026

Opportunity Ranking

Rank Idea Discovery Lane Why It May Be Best Now Evidence Freshness Catalyst Window Asymmetry Main Reason to Reject
1 Redcentric still prices the stub too cheap Europe / UK small-cap IT services / asset sale / tender offer / balance-sheet reset RCN last closed at 131.00p while the board intends a 160p tender after the GBP122.85 million data-centre sale closed and the capital-reduction vote passed. At that price, the market is effectively marking the surviving MSP stub at only about 115p per surviving share, even though the go-forward business produced GBP18.8 million of FY25 adjusted EBITDA and 90.4% recurring revenue in H1 FY26. Official sale-completion RNS dated May 1, 2026, official GM result dated May 13, 2026, official operating data from company results materials, and latest available close checked May 14, 2026 Singapore time. Initial court hearing expected in the week commencing June 8, 2026, final court hearing in the week commencing June 29, 2026, tender circular in June, settlement anticipated in July, and retained sale proceeds expected by July 31, 2026. The quote is still anchored to a gross tender spread story when the more important number is the implied valuation of the remaining MSP business after cash comes back. Tender mechanics matter. If the stub deserves a low multiple, the headline 160p anchor overstates the real upside.
2 Yum China returns cash faster than the market credits Broader Asia / China consumer / capital return YUMC last traded at $46.92 when checked at 07:15 Singapore time on May 14, 2026, after the company announced about $512 million of second-half repurchase agreements inside a $1.5 billion 2026 capital-return plan. Official company release dated May 12, 2026 and live finance snapshot checked May 14, 2026. Ongoing buyback execution and the next operating print. The capital return is large enough to matter even if same-store growth stays ordinary. A current-dated Yum China article already exists in articles/, and the China-consumer discount can stay stubborn.
3 Aisin's capital return is real, but the tender math runs the wrong way Japan large-cap auto supplier / tender offer / treasury-stock cancellation Aisin approved a tender offer at JPY1,986 a share and up to JPY100 billion of repurchases, but the stock was trading materially above the tender price during this run, leaving little long-side spread for public holders. Official April 28, 2026 treasury-stock tender announcement plus live quote checks during this run. Tender period already underway and runs through fiscal 2026 year-end. The capital return is genuine. The offer price sits below the live stock price, so the headline buyback is not a clean long setup for outside buyers.
4 Ingram still faces sponsor overhang, but the block-price gap is too small U.S. IT distribution / secondary block / concurrent repurchase INGM traded at $25.83 when checked at 07:15 Singapore time on May 14, 2026 after the company agreed to repurchase $30 million of stock alongside a sponsor secondary priced at $26.00. Official secondary-offering pricing release dated May 5, 2026 and live finance snapshot checked May 14, 2026. Remaining sponsor monetisation and future use of the repurchase authorization. The company buying sponsor paper near the tape is supportive. The price gap to the last block is too narrow for this to beat Redcentric's clearer event path.

Selected opportunity: Redcentric still prices the stub too cheap.

Why this one now: The sale is already done, the shareholder vote is already done, the court timetable is already public, and the current quote still understates the economic value of the post-return MSP stub.

What should surprise the reader: The important number is not the 160p tender headline. It is that buying Redcentric at 131p implies the surviving managed-services business is only being capitalised at about 115p per post-tender share, or roughly 7.3x FY25 MSP adjusted EBITDA after assuming the company returns only GBP90 million and leaves around GBP19 million drawn on the revolver.

Why This Is the Best Opportunity Right Now

Redcentric wins because the thesis is already past the fragile stage where everything depends on a promised transaction.

The company has completed the sale of its data-centre business. It has received GBP115.4 million upfront, expects the retained GBP7.45 million balance by July 31, 2026, plans to return more than GBP90 million to shareholders at 160p, and has already won the May 13, 2026 shareholder vote needed to keep that process moving. The next gates are procedural, not conceptual. Redcentric sale completion RNS, May 1, 2026 Redcentric capital-reduction vote result, May 13, 2026 Redcentric capital-reduction circular timetable, April 24, 2026

The other candidates were real, but less clean. Yum China is liquid and shareholder-friendly, but the discount there is partly the normal price of China exposure. Aisin's tender price is below the tape. Ingram's sponsor overhang is interesting, but the economic gap is modest. Redcentric is the one case where completed asset monetisation, an explicit return price, and the current quote still disagree in a way that can be underwritten.

What Should Surprise the Reader

The surprise is not that Redcentric sold a data-centre business and promised a tender.

The surprise is that after a closed sale, a passed shareholder vote, and a stated 160p return price, the market still prices the remaining MSP business as if it deserves only a middling stub value. At 131p, this is not mainly a tender spread. It is a cheap-go-forward-business question wearing a tender-offer costume.

The Setup

Redcentric used to be two businesses sitting inside one listed wrapper: a capital-intensive data-centre arm and a recurring-revenue UK managed-services provider.

Management separated those businesses, agreed the sale of the data-centre unit to Stellanor Datacenters, and then completed the transaction on April 30, 2026 for estimated proceeds of GBP122.85 million. The board said the initial settlement was GBP115.4 million, with the remaining GBP7.45 million retained for post-completion adjustments and expected by July 31, 2026. After allowing for about GBP21 million of debt repayment and about GBP5 million of transaction costs, the board said the company was indicating a shareholder return of GBP90 million through an equity tender at 160p a share. Redcentric sale completion RNS, May 1, 2026

On May 13, 2026, shareholders approved the capital reduction required to create the distributable reserves for that return. The company has said the initial court hearing is expected in the week commencing June 8, 2026, with the final court hearing and effectiveness of the reduction expected in the week commencing June 29, 2026. Redcentric capital-reduction vote result, May 13, 2026 Redcentric capital-reduction circular timetable, April 24, 2026

That leaves one live question: what is the remaining MSP business worth after the return cash leaves the building?

The Market Price

Market Level Current Reading Source / Timestamp Why It Matters
RCN latest available close 131.00p Market-data page showing the May 13, 2026 close, checked May 14, 2026 at 12:34 Singapore time Current entry reference before the London open.
Planned tender price 160.00p Redcentric sale-completion RNS, May 1, 2026 Public cash-return anchor.
Intended shareholder return More than GBP90 million Redcentric sale-completion RNS, May 1, 2026 Size of the cash extraction from the wrapper.
Implied tender capacity at 160p About 56.25 million shares Calculated from the GBP90 million planned return About 35.3% of the current share count.
Current equity value About GBP208.7 million Calculated from 131.00p and 159.32 million shares in issue Shows how much of today's value is just cash that is meant to come back.
Implied residual equity value after a GBP90 million return About GBP118.7 million Calculated from the two rows above The real number the market is assigning to the go-forward MSP.
Implied residual share price on surviving shares About 115.2p Calculated using current market value, planned return, and surviving share count Strips out the headline tender optics and isolates stub valuation.
MSP recurring revenue mix 90.4% of H1 FY26 revenue Redcentric H1 FY26 results presentation, December 10, 2025 The remaining business is not a low-quality project portfolio.
MSP H1 FY26 revenue GBP66.8 million Redcentric H1 FY26 results presentation, December 10, 2025 Operating scale of the continuing business.
MSP H1 FY26 adjusted EBITDA GBP9.1 million Redcentric H1 FY26 results presentation, December 10, 2025 Current earnings run-rate anchor.
MSP FY25 adjusted EBITDA GBP18.8 million Redcentric H1 FY26 results presentation, December 10, 2025 Annualised valuation anchor for the continuing business.
Post-sale revolver drawings About GBP19 million max drawn Redcentric H1 FY26 results presentation, December 10, 2025 Lets you estimate residual enterprise value more honestly.
Implied residual EV / FY25 MSP EBITDA About 7.3x Calculated from residual equity value plus expected drawings Useful shorthand for the stub valuation after cash comes back.

The Positioning

The key flow here is corporate, not speculative.

The board has already sold the capital-heavy business, already laid out the return framework, already cut the revolver target from GBP60 million to GBP30 million, and already told you it may also make on-market purchases of its own shares when attractive. This is not a hope-and-pray activist letter. It is a company simplifying itself and trying to hand cash back while leaving a cleaner, less capex-hungry MSP behind. Redcentric sale completion RNS, May 1, 2026 Redcentric H1 FY26 results presentation, December 10, 2025

What I do not have is a clean live read on short interest, borrow cost, or derivatives positioning during this run. This is not a squeeze setup. It is a balance-sheet and capital-allocation setup. The meaningful position is the company itself becoming the largest forced buyer of its own equity if the tender proceeds.

The Catalyst

The catalyst path is visible and dated.

The sale completed on April 30. Shareholders approved the capital reduction on May 13. The initial court hearing is expected in the week commencing June 8. The final court hearing and effectiveness of the reduction are expected in the week commencing June 29. The company expects the tender circular in June and settlement in July. The retained GBP7.45 million from the sale is expected by July 31 once adjustments are finished. Redcentric sale completion RNS, May 1, 2026 Redcentric capital-reduction circular timetable, April 24, 2026

That matters because every procedural step reduces the discount investors apply to promised cash. The market does not need to love the stub. It only needs to stop acting as if the return cash is still hypothetical.

The Gap

The market appears to be treating Redcentric as if the only relevant question is whether the 160p tender actually arrives.

That is too shallow.

If Redcentric returns GBP90 million at 160p, it can retire about 35.3% of its current share count. Buying the stock at 131p today does not give you a full-share path to 160p. It gives you a mixed package: some cash back at 160p, plus a continuing MSP stub. The more important judgment is what that stub is worth.

At today's quote, the answer is only about 115.2p per surviving share, which implies roughly GBP118.7 million of residual equity value. Add the expected GBP19 million of remaining revolver drawings and the residual enterprise value is about GBP137.7 million, or roughly 7.3x FY25 MSP adjusted EBITDA of GBP18.8 million. For a UK managed-services platform with 90.4% recurring revenue in H1 FY26, lower capex intensity after the sale, and management explicitly targeting stronger cash conversion, that is not an obviously generous valuation. Redcentric H1 FY26 results presentation, December 10, 2025

The market may still be carrying the memory of the old mixed wrapper. The business that remains is cleaner than the wrapper that was sold.

The Payoff Map

One possible expression is long RCN common stock.

That is the cleanest instrument because the thesis is about a priced cash return, court-driven de-risking, and rerating of a simpler operating stub. There is no listed options market that I could responsibly verify during this run, and the relevant upside is not primarily a volatility event. It is a capital-allocation event.

The right way to think about the payoff is not "131p to 160p." The right way is "131p today against a mixed future package whose current quote implies only 115.2p for the surviving stub."

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Time Horizon Conditions Required Evidence Quality
Top Case 25% RCN 155.0p +18.3% 1 to 3 months Court timetable holds, the tender circular confirms the 160p structure broadly as indicated, most of the retained GBP7.45 million is released, and the market values the surviving MSP at about 9.4x FY25 MSP EBITDA. Medium
Base Case 50% RCN 145.0p +10.7% 1 to 3 months The capital reduction clears on schedule, the return remains about GBP90 million, and the market rerates the post-return stub toward a still-reasonable 8.5x FY25 MSP EBITDA. Medium / High
Bottom Case 25% RCN 112.0p -14.5% 1 to 3 months Court or tender timing slips, the board returns less than investors expect, or the market decides the remaining MSP deserves only a harsh mid-single-digit EBITDA multiple. Medium
Invalidation / Stop Condition n/a Sustained move below RCN 112.0p n/a n/a Meaningful court delay, a material reduction in the indicated return, or new evidence that the remaining MSP cash generation is materially weaker than management has framed. Medium

Probability-weighted expected value: approximately +6.3% on price alone, using the scenario returns above. This excludes any benefit from a larger-than-indicated release of retained sale proceeds or incremental on-market buybacks.

Current market price / level: RCN 131.00p, latest available close on May 13, 2026.

Timestamp: checked May 14, 2026 at 12:34 Singapore time, before the London market open.

Primary instrument: Redcentric common stock, RCN.

Alternative expressions considered: waiting for the court timetable to advance before entry, or trying to anchor everything mechanically to 160p. Waiting reduces procedural risk but gives up part of the rerating. Using 160p as the direct target overstates the real economics because only part of a position can be tendered if the offer is full.

Confidence: Medium.

What Could Go Wrong

The strongest counterargument is that the stub is not cheap at all.

A business with slow top-line growth, modest margins, and a mixed history can absolutely deserve only 7x or lower EBITDA, especially in a UK small-cap wrapper. If the market is applying that discount for sound reasons, then the tender is simply returning excess capital, not revealing a deeper valuation mistake.

There is also mechanical risk. The board said "in excess of GBP90 million" and still has post-completion adjustments outstanding. The tender circular is not yet published. Court approval is still needed. If the final shape is less generous or slower than investors assume, the stock can sag even while the broad thesis remains directionally right.

What Would Prove This Wrong

This thesis fails if the tender path weakens or if the remaining MSP business proves less cash-generative than the sale narrative implies.

It is wrong if one or more of the following happens:

  • the court process is delayed materially beyond the current June timetable;
  • the tender price or return size is cut meaningfully from the current indication;
  • the retained GBP7.45 million balance becomes a real dispute rather than a timing issue;
  • or new disclosures show that the remaining MSP cannot sustain the cash conversion, margin profile, or debt reduction now implied by management's framing.

That would mean the market was not underpricing a cleaner stub. It was pricing the real operating quality correctly.

Bottom Line

Redcentric is no longer mainly a sale story. It is a stub-valuation story. The company has already sold the data-centre arm, already mapped a 160p tender, and already secured the shareholder vote needed to keep the process moving. At 131p, the market is still valuing the remaining MSP business at only about 115p per surviving share, or roughly 7.3x FY25 MSP EBITDA after allowing for remaining drawings. That is not absurdly cheap, but it is cheap enough to matter, especially if the June and July mechanics keep falling into place.

Best trade strategy: Long RCN common stock. The edge is in the stub math, not in an options structure.

Sources